Healthcare / Medical Care FacilitiesTokyo
$761.00
-2.00 (-0.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $-88.8M · quality 13.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
1654.3x
↑EV/EBITDA
14.1x
↑ROE
0.1%
↓Gross Margin
10.6%
↓Debt/Equity
3.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.7%
FCF CAGR
—
FCF margin
-1.3%
FCF / Net income
-87.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.66B · net income $1.0M · FCF $-88.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.66B | $6.66B | $6.28B | $5.92B | $4.90B |
| Net Income | $1.0M | $1.0M | $98.3M | $67.9M | $-253.9M |
| EBITDA | $235.9M | $235.9M | $296.6M | $224.8M | $-138.6M |
| EPS | — | — | 45.60 | 31.36 | -121.82 |
| Gross Margin | 10.6% | 10.6% | 10.9% | 8.7% | 5.0% |
| Operating Margin | 1.6% | 1.6% | 2.0% | 0.3% | -4.4% |
| Net Margin | 0.0% | 0.0% | 1.6% | 1.1% | -5.2% |
| Balance Sheet | |||||
| Debt/Equity | 3.56 | 3.56 | 3.24 | 3.07 | 3.27 |
| Current Ratio | 2.41 | 2.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-88.8M | $-88.8M | $215.4M | $-266.1M | $-739.5M |
| Returns | |||||
| ROE | 0.1% | 0.1% | 8.2% | 5.9% | -23.4% |
| Valuation | |||||
| P/E | 1654.35 | 1654.35 | 26.64 | 19.99 | — |
| EV/EBITDA | 14.13 | 14.13 | 13.83 | 12.75 | — |
| P/B | 1.34 | 1.34 | 2.17 | 1.17 | 1.36 |
| Growth & Yield | |||||
| Revenue Growth | 6.1% | 6.1% | 6.1% | 20.6% | — |
| EPS Growth | — | — | 45.4% | 125.7% | — |
| Dividend Yield | 1.6% | 1.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.7%
Start / end P/E
n/dx → n/dx
EPS bridge
45.60 → n/d
Residual
-21.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.